Zafgen Inc. (NASDAQ:ZFGN) traded up 3.7% during mid-day trading on Monday . The stock traded as high as $3.17 and last traded at $3.06, with a volume of 675,584 shares. The stock had previously closed at $2.95.

ZFGN has been the subject of several research analyst reports. FBR & Co reissued a “buy” rating on shares of Zafgen in a research report on Monday, June 13th. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research report on Thursday, May 12th. Leerink Swann reissued a “market perform” rating and issued a $6.00 target price on shares of Zafgen in a research report on Wednesday, July 20th. Cowen and Company downgraded shares of Zafgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 20th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $19.00 target price on shares of Zafgen in a research report on Tuesday, April 5th. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Zafgen presently has a consensus rating of “Hold” and a consensus price target of $9.22.

The company’s 50-day moving average is $5.84 and its 200-day moving average is $6.47. The firm’s market capitalization is $85.64 million.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.09. During the same quarter in the prior year, the company earned ($0.53) EPS. On average, equities research analysts anticipate that Zafgen Inc. will post ($2.62) earnings per share for the current fiscal year.

In other news, CFO Patricia L. Allen acquired 16,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The stock was acquired at an average cost of $3.12 per share, with a total value of $49,920.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Frances K. Heller acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The shares were purchased at an average cost of $2.99 per share, with a total value of $29,900.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $29,900. The disclosure for this purchase can be found here.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.